These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30060231)

  • 1. Ebolavirus Chimerization for the Development of a Mouse Model for Screening of Bundibugyo-Specific Antibodies.
    Ilinykh PA; Graber J; Kuzmina NA; Huang K; Ksiazek TG; Crowe JE; Bukreyev A
    J Infect Dis; 2018 Nov; 218(suppl_5):S418-S422. PubMed ID: 30060231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk.
    King LB; West BR; Moyer CL; Gilchuk P; Flyak A; Ilinykh PA; Bombardi R; Hui S; Huang K; Bukreyev A; Crowe JE; Saphire EO
    Nat Commun; 2019 Apr; 10(1):1788. PubMed ID: 30996276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.
    Gilchuk P; Kuzmina N; Ilinykh PA; Huang K; Gunn BM; Bryan A; Davidson E; Doranz BJ; Turner HL; Fusco ML; Bramble MS; Hoff NA; Binshtein E; Kose N; Flyak AI; Flinko R; Orlandi C; Carnahan R; Parrish EH; Sevy AM; Bombardi RG; Singh PK; Mukadi P; Muyembe-Tamfum JJ; Ohi MD; Saphire EO; Lewis GK; Alter G; Ward AB; Rimoin AW; Bukreyev A; Crowe JE
    Immunity; 2018 Aug; 49(2):363-374.e10. PubMed ID: 30029854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
    Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.
    Wec AZ; Bornholdt ZA; He S; Herbert AS; Goodwin E; Wirchnianski AS; Gunn BM; Zhang Z; Zhu W; Liu G; Abelson DM; Moyer CL; Jangra RK; James RM; Bakken RR; Bohorova N; Bohorov O; Kim DH; Pauly MH; Velasco J; Bortz RH; Whaley KJ; Goldstein T; Anthony SJ; Alter G; Walker LM; Dye JM; Zeitlin L; Qiu X; Chandran K
    Cell Host Microbe; 2019 Jan; 25(1):39-48.e5. PubMed ID: 30629917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop.
    Mire CE; Geisbert TW
    Trends Mol Med; 2017 Aug; 23(8):669-671. PubMed ID: 28697885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model.
    Duehr J; Wohlbold TJ; Oestereich L; Chromikova V; Amanat F; Rajendran M; Gomez-Medina S; Mena I; tenOever BR; García-Sastre A; Basler CF; Munoz-Fontela C; Krammer F
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.
    Williamson LE; Flyak AI; Kose N; Bombardi R; Branchizio A; Reddy S; Davidson E; Doranz BJ; Fusco ML; Saphire EO; Halfmann PJ; Kawaoka Y; Piper AE; Glass PJ; Crowe JE
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30728263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates.
    Bornholdt ZA; Herbert AS; Mire CE; He S; Cross RW; Wec AZ; Abelson DM; Geisbert JB; James RM; Rahim MN; Zhu W; Borisevich V; Banadyga L; Gunn BM; Agans KN; Wirchnianski AS; Goodwin E; Tierney K; Shestowsky WS; Bohorov O; Bohorova N; Velasco J; Ailor E; Kim D; Pauly MH; Whaley KJ; Alter G; Walker LM; Chandran K; Zeitlin L; Qiu X; Geisbert TW; Dye JM
    Cell Host Microbe; 2019 Jan; 25(1):49-58.e5. PubMed ID: 30629918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and characterization of two GP-specific monoclonal antibodies, which synergistically protect non-human primates against Ebola lethal infection.
    Shcheblyakov D; Esmagambetov I; Simakin P; Kostina L; Kozlov A; Tsibezov V; Grebennikova T; Chifanov D; Rumyantseva I; Boyarskaya N; Sizikova T; Shagarova N; Andrus А; Shatohina I; Syromyatnikova S; Kovalchuk A; Pantyukhov V; Borisevich S; Zubkova O; Tukhvatulin A; Logunov D; Naroditsky B; Gintsburg A
    Antiviral Res; 2019 Dec; 172():104617. PubMed ID: 31593751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.
    Wec AZ; Herbert AS; Murin CD; Nyakatura EK; Abelson DM; Fels JM; He S; James RM; de La Vega MA; Zhu W; Bakken RR; Goodwin E; Turner HL; Jangra RK; Zeitlin L; Qiu X; Lai JR; Walker LM; Ward AB; Dye JM; Chandran K; Bornholdt ZA
    Cell; 2017 May; 169(5):878-890.e15. PubMed ID: 28525755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of an antibody for pan-ebolavirus therapy.
    Furuyama W; Marzi A; Nanbo A; Haddock E; Maruyama J; Miyamoto H; Igarashi M; Yoshida R; Noyori O; Feldmann H; Takada A
    Sci Rep; 2016 Feb; 6():20514. PubMed ID: 26861827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope.
    West BR; Moyer CL; King LB; Fusco ML; Milligan JC; Hui S; Saphire EO
    mBio; 2018 Sep; 9(5):. PubMed ID: 30206174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-ebolavirus protective therapy by two multifunctional human antibodies.
    Gilchuk P; Murin CD; Cross RW; Ilinykh PA; Huang K; Kuzmina N; Borisevich V; Agans KN; Geisbert JB; Zost SJ; Nargi RS; Sutton RE; Suryadevara N; Bombardi RG; Carnahan RH; Bukreyev A; Geisbert TW; Ward AB; Crowe JE
    Cell; 2021 Oct; 184(22):5593-5607.e18. PubMed ID: 34715022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection.
    Flyak AI; Shen X; Murin CD; Turner HL; David JA; Fusco ML; Lampley R; Kose N; Ilinykh PA; Kuzmina N; Branchizio A; King H; Brown L; Bryan C; Davidson E; Doranz BJ; Slaughter JC; Sapparapu G; Klages C; Ksiazek TG; Saphire EO; Ward AB; Bukreyev A; Crowe JE
    Cell; 2016 Jan; 164(3):392-405. PubMed ID: 26806128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP.
    Reynard O; Volchkov VE
    J Infect Dis; 2015 Oct; 212 Suppl 2():S372-8. PubMed ID: 26232760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.
    Flyak AI; Kuzmina N; Murin CD; Bryan C; Davidson E; Gilchuk P; Gulka CP; Ilinykh PA; Shen X; Huang K; Ramanathan P; Turner H; Fusco ML; Lampley R; Kose N; King H; Sapparapu G; Doranz BJ; Ksiazek TG; Wright DW; Saphire EO; Ward AB; Bukreyev A; Crowe JE
    Nat Microbiol; 2018 Jun; 3(6):670-677. PubMed ID: 29736037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ebola virus can be effectively neutralized by antibody produced in natural human infection.
    Maruyama T; Rodriguez LL; Jahrling PB; Sanchez A; Khan AS; Nichol ST; Peters CJ; Parren PW; Burton DR
    J Virol; 1999 Jul; 73(7):6024-30. PubMed ID: 10364354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development.
    Murin CD; Gilchuk P; Crowe JE; Ward AB
    Front Immunol; 2021; 12():808047. PubMed ID: 35082794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
    Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ
    J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.